Rapamycin increases fetal hemoglobin and ameliorates the nociception phenotype in sickle cell mice.

Abstract excerpt

Fetal hemoglobin-inducing therapies are disease-modifying and ameliorate the pain phenotype in sickle cell disease (SCD). Rapamycin, a mammalian target of rapamycin (mTOR) inhibitor, increases HbF in erythroid precursor cells in vitro. We hypothesized that rapamycin would increase HbF levels and improve nociception phenotype in SCD mice. We used sine-wave electrical stimulation to examine nocifensive phenotype...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Anemia, Sickle Cell
• Share to Bone Marrow